RxDoctor Payments Data

Sara Khalil, MD

Family Medicine · Myrtle Beach, SCNPI 1699157214

Payments from drug & device makers

$5,957in general payments, 2019–2025

Across 362 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$826
  • AbbVie$821
  • Novo Nordisk$739
  • Johnson & Johnson$506
  • Astellas Pharma US Inc$445
  • Amgen$440
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,67995%
  • Education$2775%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,957 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$292,637
Medicare patients
582
Services billed
10,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide126$154,987
OzempicSemaglutide50$74,236
EliquisApixaban32$44,018
XareltoRivaroxaban28$30,436
TrulicityDulaglutide12$29,762
FarxigaDapagliflozin Propanediol19$28,811
JardianceEmpagliflozin13$21,731
Repatha SureclickEvolocumab18$20,774
LinzessLinaclotide11$15,659
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$13,593
Rosuvastatin Calcium533$8,535
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,960
Dexlansoprazole DrDexlansoprazole24$7,505
Breo ElliptaFluticasone/Vilanterol12$6,885
Atorvastatin Calcium696$6,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$155$184,749138 claims
Novo NordiskOzempic$739$74,23650 claims
PfizerEliquis$358$44,01832 claims
AstraZenecaFarxiga, Breztri Aerosphere$826$36,77131 claims
Johnson & JohnsonXarelto$506$30,43628 claims
Boehringer IngelheimJardiance$74$21,73113 claims
GSKTrelegy Ellipta, Breo Ellipta$194$20,47825 claims
AbbVieLinzess, Synthroid$821$19,47767 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →